AdAlta has released an updated brochure on Idiopathic Pulmonary Fibrosis (IPF), the debilitating lung disease for which the i-body therapeutic, AD-214, is currently in preclinical development.
The brochure displayed below introduces ‘What is IPF?’, the market potential, current therapeutics in development as well as AdAlta unique approach to tackling this disease through an i-body to a drug target called CXCR4.
The brochure can be downloaded here, more information on AdAlta’s lead i-body program, AD-214, can be found here and if you would like to receive updates on AdAlta’s progress subscribe here.
Adalta IPF white paper Jan 2019 FINAL